Recommended Dosage
The recommended dosage of tigecycline is 100 mg administered intravenously every 12 hours for 5 to 14 days. [1] DrugPatentWatch.com notes that the maximum recommended dose is 100 mg every 12 hours. [2]
Clinical Trials and Pharmacokinetics
Clinical trials have demonstrated that tigecycline has a half-life of approximately 13 hours, allowing for administration every 12 hours. The pharmacokinetics of tigecycline are linear, and the drug is eliminated primarily through the liver and kidneys. [3]
Dose Adjustment
No dosage adjustment is necessary in patients with renal or hepatic impairment. However, caution should be exercised in patients with moderate to severe hepatic impairment, as tigecycline is primarily eliminated by the liver. [1]
Monitoring and Side Effects
Monitor patients receiving tigecycline for signs of adverse effects, particularly those related to the gastrointestinal and hepatic systems. The most common side effects of tigecycline include nausea and injection site reactions. [1]
Patent Information
The patent for tigecycline is owned by Pfizer, and the compound has a broad patent covering formulations and uses up to 2028. [2]
Regulatory Approval
Tigecycline has been approved by regulatory agencies worldwide, including the US FDA, for the treatment of various infections, such as complicated intra-abdominal infections and skin and skin structure infections. [4]
Clinical Data and Studies
Several clinical trials have demonstrated the efficacy and safety of tigecycline in treating a range of infections. However, the results of these studies should be critically evaluated in the context of the patient's individual medical history and treatment preferences.
Sources:
[1] Drugs.com. (n.d.). Tigecycline. Retrieved from https://www.drugs.com/mtm/tigecycline.html
[2] DrugPatentWatch.com. (n.d.). Tigecycline Patents. Retrieved from https://www.drugpatentwatch.com/DrugPatentWatch/DrugPatent.aspx?id=1000
[3] Tigecycline Prescribing Information. (n.d.). Pfizer. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2011/021998s017lbl.pdf
[4] Pfizer. (n.d.). Tigecycline. Retrieved from https://www.pfizer.com/news/hottopics/inside_pfizer/tigecycline